Expression patterns of H3K27me3 for differentiation of breast fibroadenomas and phyllodes tumors.
Phyllodes tumor
fibroadenoma
trimethyl lysine 27 of histone 3
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
06
12
2023
accepted:
11
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
Phyllodes tumors (PTs) are rare breast tumors showing overlapping features with fibroadenomas (FAs). Diagnosis on small biopsies is challenging. New diagnostic markers are needed. Here we evaluated immunohistochemical staining of histone 3 trimethyl-lysine-27 (H3K27me3) as a diagnostic and prognostic marker in a series of PTs. Surgically removed PTs at our institution (September 1990 and July 2022) and control FAs. Tissue micro-arrays (4 cores, 2 mm Ø) stained with H3K27me3, and scored with QuPath-derived H-score. Fisher exact test, Mann-Whitney U-test and chi-squared test used for group comparison. ROC analysis applied to define cutoffs. Cox proportional hazards models were used for assessing disease-free survival (DFS), overall survival (OS), and disease-specific survival (DSS) in PTs. We included 81 patients with PTs and 44 patients with FAs. QuPath-derived H-scores of stromal H3K27me3 were statically significantly lower in PTs than in FAs (p < 0.001). We identified exploratory cutoffs to discriminate FAs from benign and malignant PTs (AUC = 0.78 and 0.73, respectively). No associations between DFS, OS, or DSS and H3K27me3 expression were found. H3K27me3 expression differs between FAs and PTs, indicating potential as diagnostic marker, but it is not predictive for DFS, OS or DSS in PTs. Further validation is needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
Zhou ZR, Wang CC, Yang ZZ, Yu XL, Guo XM. Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence. J Thorac Dis. 2016;8:3361–3368.
Anderson WJ, Fletcher CDM. Mesenchymal lesions of the breast. Histopathology. 2023;82:83–94.
Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68:5–21.
Chng TW, Gudi M, Lim SH, Li HH, Tan PH. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large patient cohort. J Clin Pathol. 2018;71:125–128.
Tse G, Koo JS, Thike AA. Phyllodes tumour. WHO Classification of Tumours Editorial Board. Breast Tumours WHO Classification of Tumours. 5th ed. Lyon: IARC; 2019.
Di Liso E, Bottoso M, Lo Mele M, Tsvetkova V, Dieci MV, Miglietta F, et al. Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. ESMO Open. 2020;5:e000843.
Tan PH. Refining the classification of breast phyllodes tumours. Pathology. 2023;55:437–448.
Rakha E, Mihai R, Abbas A, Bennett R, Campora M, Morena P, et al. Diagnostic concordance of phyllodes tumour of the breast. Histopathology. 2021;79:607–618.
Tan BY, Fox SB, Lakhani SR, Tan PH. Survey of recurrent diagnostic challenges in breast phyllodes tumours. Histopathology. 2023;82:95–105.
Turashvili G, Ding Q, Liu Y, Peng L, Mrkonijc MH. Comprehensive clinical‐pathologic assessment of malignant phyllodes tumors: proposing refined diagnostic criteria. Am J Surg Pathol. 2023;47:1195–1206.
Rosenberger LH, Quintana L, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, et al. Limited reporting of histopathologic details in a multi‐institutional academic cohort of phyllodes tumors: time for standardization. Ann Surg Oncol. 2021;28:7404–7409.
Yasir S, Gamez R, Jenkins S, Visscher DW, Nassar A. Significant histologic features differentiating cellular fibroadenoma from phyllodes tumor on core needle biopsy specimens. Am J Clin Pathol. 2014;142:362–369.
Lee A, James J, Whisker L, Rakha E, Ellis IO. Which lesions with a radiological or core biopsy diagnosis of fibroadenoma should be excised? Ann R Coll Surg Engl. 2022;104:361–366.
Shin E, Koo JS. Prognostic factors of breast phyllodes tumors. Histol Histopathol. 2023;38:865–878.
Zhang Y, Liss AL, Chung E, Pierce LJ, Kleer CG. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression. Breast Cancer Res Treat. 2016;158(158):21–28.
Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger‐Saal S, Howlin J, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012;6:494–506.
Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt D, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
Delgado A, Guddati AK. Clinical endpoints in oncology – a primer. Am J Cancer Res. 2021;11:1121–1131.
Bae WK, Yoo KH, Lee JS, Kim Y, Chung I‐J, Park MH, et al. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER‐positive breast cancers. Mol Carcinog. 2015;54:1172–1180.
Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 2012;8:59–65.
Anwar T, Gonzalez ME, Kleer CG. Noncanonical functions of the polycomb group protein EZH2 in breast cancer. Am J Pathol. 2021;191:774–783.
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci. 2003;100:11606–11611.
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47:701–706.
Cai M‐Y, Hou J‐H, Rao H‐L, Luo R‐Z, Li M, Pei X‐Q, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011;17:12–20.
He L‐R, Liu M‐Z, Li B‐K, Rao H‐L, Liao Y‐J, Guan X‐Y, et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009;9:461.
Laugesen A, Westergaard Højfeldt J, Helin K. Molecular mechanisms directing PRC2 recruitment and H3K27 methylation. Mol Cell. 2019;74:8–18.
Tan J, Ong CK, Lim WK, Ng CCY, Thike AA, Ng LM, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015;47:1341–1345.
Pareja F, Geyer FC, Kumar R, Selenica P, Piscuoglio S, Ng CKY, et al. Phyllodes tumors with and without fibroadenoma‐like areas display distinct genomic features and may evolve through distinct pathways. NPJ Breast Cancer. 2017;3:40.
Tsang JY, Shao Y, Poon IK, Ni YB, Kwan JS, Chow C, et al. Analysis of recurrent molecular alterations in phyllodes tumour of breast: insights into prognosis and pathogenesis. Pathology. 2022;54:678–685.
Meyer B, Stirzaker C, Ramkomuth S, Harvey K, Chan B, Lee CS, et al. Detailed DNA methylation haracterization of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma. J Pathol. 2024;262:480–494.
Cleven AH, Al Sannaa GA, Briaire‐de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, et al. Loss of H3K27 tri‐methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582–590.
Ilyas M, Grabsch H, Ellis IO, Womack C, Brown R, Berney D, et al. Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology. 2013;62:827–839.